<DOC>
	<DOC>NCT02955953</DOC>
	<brief_summary>The study will aim to evaluate the following: - Whether there are any differences in the way the body handles LY2963016 U-200 and LY2963016 U-100. - How well-tolerated LY2963016 U-200 is compared with LY2963016 U-100. - How LY2963016 U-200 affects the level of blood sugar in the body compared with LY2963016 U-100. The study will last up to 17 weeks for each participant, including initial screening and follow up.</brief_summary>
	<brief_title>A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Have a body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/mÂ²) Have a fasting plasma glucose less than (&lt;) 6.0 millimoles per liter (mmol/L) (108 milligram per deciliter [mg/dL]) Have venous access sufficient to allow for blood sampling and clamp procedures per protocol Have known allergies to the study drug, or any components of the formulation Have donated or had a blood loss of 450 milliliter (mL) within 3 months prior to study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>